Dogwood Therapeutics (DWTX) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dogwood Therapeutics (DWTX) has outperformed Stablecoin Development (SDEV) over the past year, losing 83.7% versus a loss of 88.4%. Over five years, DWTX leads with a -99.2% price change compared with -100.0% for SDEV. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $36.9 million), about 1.1 times the size.
On valuation, Dogwood Therapeutics trades at a lower trailing P/E (0.1x vs 0.2x for Stablecoin Development).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | SDEV |
|---|---|---|
| Share price | $1.04 | $0.50 |
| Market cap | $39.57M | $36.90M |
| 1-day change | -2.36% | -10.30% |
| YTD return | -75.12% | -98.23% |
| 1-year return | -83.68% | -88.37% |
| 5-year return | -99.16% | -99.98% |
| P/E ratio (TTM) | 0.10 | 0.19 |
| EPS (TTM) | $10.26 | $2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.26M | $-630.78M |
| 52-week high | $7.04 | $99.75 |
| 52-week low | $0.901 | $0.467 |
| Distance from 52-week high | -85.31% | -99.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +1252.66% | — |
| Average volume | 89.88K | 16.98M |
| Shares outstanding | 38.23M | 73.80M |
| Employees | 8 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Stablecoin Development trades at a higher earnings multiple (0.2x vs 0.1x trailing P/E).
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
DWTX vs SDEV FAQ
Which is bigger, Dogwood Therapeutics or Stablecoin Development?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $36.90M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, DWTX or SDEV?
DWTX returned -83.68% over the past 12 months, compared with -88.37% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DWTX or SDEV?
DWTX has the lower trailing P/E at 0.1, versus 0.2 for SDEV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Dogwood Therapeutics and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.